Today’s trading session in the NIFTY 50 index was marked by a blend of significant gains and losses among various stocks.
UPL Ltd. led the pack with an impressive surge, closing at ₹602.40, marking a 2.94% increase from the previous day. This gain positioned the stock as the day’s top performer in the NIFTY 50.
Stock | Current Price | Last Close | % Change |
---|---|---|---|
UPL | ₹602.4 | ₹585.2 | 2.94% |
UltraTech Cement | ₹9670.9 | ₹9413.55 | 2.73% |
Adani Enterprises | ₹2855.8 | ₹2822.15 | 1.19% |
LTI Mindtree | ₹5770.65 | ₹5708.7 | 1.09% |
Bajaj Auto | ₹6138.4 | ₹6075.7 | 1.03% |
Stock | Current Price | Last Close | % Change |
---|---|---|---|
Dr. Reddy’s Laboratories Ltd. | ₹5473.5 | ₹5763.9 | -5.04% |
Cipla Ltd. | ₹1202.3 | ₹1219.1 | -1.38% |
Axis Bank Ltd. | ₹1116.5 | ₹1131.2 | -1.3% |
Bharat Petroleum Corporation Ltd. | ₹465.5 | ₹470.45 | -1.05% |
Mahindra & Mahindra Ltd. | ₹1652.2 | ₹1668.55 | -0.98% |
Conversely, Dr. Reddy’s Laboratories Ltd. experienced a notable decline, with its stock price falling to ₹5,473.50, a decrease of 5.04% from the previous close, making it the biggest loser of the day.
UltraTech Cement Ltd. also had a strong showing, with a 2.73% increase in its share price. Adani Enterprises, LTI Mindtree, and Bajaj Auto also joined the list of gainers, showing a positive trend in their respective stock prices.
On the flip side, other stocks like Cipla Ltd., Axis Bank Ltd., Bharat Petroleum Corporation Ltd., and Mahindra & Mahindra Ltd. recorded declines in their share prices, reflecting the diverse movements within the index.
Read Next: Apple’s Already Met A Major Chunk Of Its Promised PLI Scheme Target
Engineered by Benzinga Neuro, Edited by Utkarsh Roshan
The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
Don't miss a beat on the share market. Get real-time updates on top stock movers and trading ideas on Benzinga India Telegram channel.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.